

Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

HSJD-DIPG-007

RRID:CVCL_VU70

Type: Cell Line

Proper Citation

RRID:CVCL_VU70

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VU70

Proper Citation: RRID:CVCL_VU70

Description: Cell line HSJD-DIPG-007 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse intrinsic pontine glioma

Defining Citation: [PMID:25628092](#), [PMID:27325687](#), [PMID:28947132](#), [PMID:31439867](#), [PMID:32229503](#), [PMID:34078608](#), [PMID:34732238](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HSJD-DIPG-007

Synonyms: HSJD-DIPG007, DIPG007, Hospital Sant Joan de Deu-Diffuse Intrinsic Pontine Glioma-007

Cross References: cancercellines:CVCL_VU70, Cell_Model_Passport:SIDM01714, DepMap:ACH-002348, GEO:GSM4969594, GEO:GSM4969595, GEO:GSM4969596, GEO:GSM4969597, GEO:GSM4969623, GEO:GSM4969655, GEO:GSM4969656, GEO:GSM4969658, GEO:GSM4969662, GEO:GSM4969663, GEO:GSM4969664, GEO:GSM5356018, Wikidata:Q94303494

ID: CVCL_VU70

Record Creation Time: 20220427T220616+0000

Record Last Update: 20260920T004123+0000

Ratings and Alerts

No rating or validation information has been found for HSJD-DIPG-007.

No alerts have been found for HSJD-DIPG-007.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chua AJ, et al. (2026) Delivery of ATSP-7041 by Minimally Invasive Nasal Depot (MIND) to Target Diffuse Intrinsic Pontine Glioma. Molecular cancer therapeutics, 25(6), 992.

Metselaar DS, et al. (2024) Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors. Cell reports. Medicine, 5(9), 101700.

Sharma M, et al. (2024) Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. Molecular cancer therapeutics, 23(1), 24.

Jane EP, et al. (2023) Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas. Molecular oncology, 17(9), 1821.

Mota M, et al. (2023) Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas. Proceedings of the National Academy of Sciences of the United States of America, 120(18), e2221175120.

Venneti S, et al. (2023) Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer discovery, 13(11), 2370.

Metselaar DS, et al. (2022) AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. iScience, 25(6), 104398.

Panditharatna E, et al. (2022) BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer discovery, 12(12), 2880.

Chastkofsky MI, et al. (2021) Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical cancer research : an official journal

of the American Association for Cancer Research, 27(6), 1766.

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. *Cancer cell*, 38(3), 334.

Fortin J, et al. (2020) Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. *Cancer cell*, 37(3), 308.